Great Basin Scientific, Inc. (NASDAQ:GBSN) went lower by -1.131% to close at $ 0.201. The company exchanged total volume of 8.57 million shares throughout course of last trade however it holds an average trading capacity of 3.56 million shares. Shares of company began trading at $0.209 climbed to high of $0.226 touched the low of $0.201.
The company is trading below its 50-day moving averages of 0.494 and down from 200-day moving averages of 2.885. The firm its price to sale ratio was 3.193.
The average true range of Great Basin Scientific, Inc.’s (GBSN) is recorded at 0.06 and the relative strength index of the stock stands 22.17. The stock price is going above to its 52 week low with 11.05% and lagging behind from its 52 week high with -99.97%. Analyst recommendation for this stock stands at 3.00. A look on the firm performance, its monthly performance is -40.88% and a quarterly performance of -89.31%. The stock price is trading downbeat from its 200 days moving average with -99.36% and down from 50 days moving average with -75.98%.
CTI BioPharma Corp. (NASDAQ:CTIC) dropped -2.481% and closed the trade at $ 0.393. The company recorded a trading capacity of 1.27 million shares below its three months average daily volume of 1.44 million shares. During the last trade, shares reached to high price of $0.416 and touched the low price of $0.384. The stock’s 50-day moving average is noted at $0.356 and its 200-day moving average is stands at $0.452.
Additionally, the company has EPS of -0.324. The company has market capitalization of $109.88M.
According to ZACKS data, different Brokerage Firms rated the stock about their BUY, SELL or HOLD recommendations. 1 Month Ago, shares have been suggested as “BUY” from “0” brokerage firms and recommended as “Strong Buy” by “0” brokerage firms. 0” brokerage firms have issued “Sell” rating for the company and “Strong Sell” rating was issued by “1” brokerage firms. “2” brokerage firms have rated the company as a “Hold”. The Corporation has average brokerage recommendation (ABR) of 3.67 based on consensus of the brokerage firms issuing ratings.
CTI BioPharma Corp.’s (CTIC) has price-to-cash ratio of 1.43 and price to sale ratio of 1.95. The company gross profit margin is 96.60%. A look on the firm performance, its monthly performance is 17.07% and a quarterly performance of -9.66%. The stock price is moving up from its 20 days moving average with 10.02% and isolated positively from 50 days moving average with 10.10%.